Copanlisib联合利妥昔单抗和苯达莫司汀治疗不适合移植的复发/难治性弥漫大B细胞淋巴瘤患者:意大利淋巴瘤基金会FIL Copa-BR多中心II期试验结果
这项II期单臂多中心试验评估copanlisib联合利妥昔单抗和苯达莫司汀(copa-BR)用于不适合自体干细胞移植(ASCT)和CAR-T治疗的复发/难治性弥漫大B细胞淋巴瘤(DLBCL)。37例患者(年龄68-87岁,既往1-2线治疗后复发/难治)接受6周期copa-BR后copanlisib维持最多12周期,主要终点12个月无进展生存(PFS)。总缓解率24.3%,完全缓解13.5%;中位随访20个月,12个月PFS率和总生存率分别为25.1%和44.5%。因疗效有限、耐受性差及出现替代治疗,试验提前终止;copa-BR活性有限且安全性不利,不支持进一步研究该联合方案。
要点
- copa-BR在ASCT和CAR-T不合格的R/R DLBCL中总缓解率24.3%,完全缓解13.5%。
- 12个月PFS率25.1%,12个月总生存率44.5%,中位随访20个月。
- ≥3级毒性包括中性粒细胞减少56.8%、感染27.0%(含6例COVID-19感染死亡,病死率25%)和血小板减少16.2%。
核心结论
- copa-BR在ASCT和CAR-T不合格的R/R DLBCL中显示有限活性和不利的安全性,不支持进一步研究该联合方案。
研究设计与样本
- II期、单臂、多中心试验,评估copanlisib联合利妥昔单抗和苯达莫司汀(copa-BR)用于不适合ASCT和CAR-T治疗的R/R DLBCL患者。
- 患者接受6周期copa-BR,随后copanlisib维持最多12周期;主要终点为12个月无进展生存(PFS)。
- 共纳入37例患者,年龄68-87岁,均为既往1-2线治疗后复发/难治。
主要发现
- 总缓解率为24.3%,完全缓解率为13.5%。
- 中位随访20个月,12个月PFS率为25.1%,12个月总生存率为44.5%。
- ≥3级毒性包括中性粒细胞减少56.8%、感染27.0%(包括6例COVID-19感染死亡,病死率25%)和血小板减少16.2%。
- 因疗效有限、耐受性差及出现替代治疗,试验提前终止。
局限性
- 因疗效有限、耐受性差及出现替代治疗,试验提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment options for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR)-T-cell therapy remain limited. The PI3K inhibitor copanlisib has shown activity as a single agent in DLBCL. This phase II, single-arm, multicentre trial evaluated copanlisib with rituximab and bendamustine (copa-BR) in ASCT- and CAR-T-ineligible R/R DLBCL. Patients received six cycles of copa-BR, followed by up to 12 cycles of copanlisib maintenance. The primary end-point was 12-month progression-free survival (PFS). Thirty-seven patients (aged 68-87 years, R/R after 1-2 prior lines) were enrolled. The overall response rate was 24.3%, with complete responses in 13.5%. After a median follow-up of 20 months, the 12-month PFS and overall survival rates were 25.1% and 44.5% respectively. Grade ≥3 toxicities included neutropenia (56.8%), infections (27.0%, including 6 death due to COVID-19 infection with 25% fatality) and thrombocytopenia (16.2%). Due to limited efficacy, poor tolerability and emerging alternative treatments, the trial was terminated prematurely. Copa-BR showed limited activity and an unfavourable safety profile, discouraging further investigation of this combination in ASCT- and CAR-T-ineligible R/R DLBCL.
引用
- Novo M, Frascione PMM, Castellino A, et al. Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL). Br J Haematol. 2025. PMID: 40495420. doi:10.1111/bjh.20204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。